Patient characteristics
| Characteristic . | N = 55 . |
|---|---|
| Age, median (range), y | 36 (19-79) |
| Male, n (%) | 24 (43.6) |
| White, n (%) | 46 (83.6) |
| ECOG status, n (%) | |
| 0 | 36 (65.5) |
| 1 | 18 (32.7) |
| 2 | 1 (1.8) |
| Months since HL diagnosis, median (range) | 13.8 (3-98) |
| Disease stage at diagnosis, n (%) | |
| I | 3 (5.5) |
| II | 23 (41.8) |
| III | 14 (25.5) |
| IV | 15 (27.3) |
| Frontline therapy received, n (%)* | |
| ABVD† | 50 (90.9) |
| Stanford V | 3 (5.5) |
| AVD | 1 (1.8) |
| VAMP | 1 (1.8) |
| Response to frontline therapy, n (%) | |
| Primary refractory‡ | 28 (50.9) |
| Relapsed | 27 (49.1) |
| CR > 1 y | 17 |
| CR ≤ 1 y | 10 |
| Prior cancer-related radiotherapy, n (%) | 15 (27.3) |
| Baseline disease characteristics, n (%) | |
| B symptoms | 12 (21.8) |
| Bulky disease§ | 5 (9.1) |
| Extranodal disease | 17 (30.9) |
| Bone marrow involvement | 9 (16.4) |
| Characteristic . | N = 55 . |
|---|---|
| Age, median (range), y | 36 (19-79) |
| Male, n (%) | 24 (43.6) |
| White, n (%) | 46 (83.6) |
| ECOG status, n (%) | |
| 0 | 36 (65.5) |
| 1 | 18 (32.7) |
| 2 | 1 (1.8) |
| Months since HL diagnosis, median (range) | 13.8 (3-98) |
| Disease stage at diagnosis, n (%) | |
| I | 3 (5.5) |
| II | 23 (41.8) |
| III | 14 (25.5) |
| IV | 15 (27.3) |
| Frontline therapy received, n (%)* | |
| ABVD† | 50 (90.9) |
| Stanford V | 3 (5.5) |
| AVD | 1 (1.8) |
| VAMP | 1 (1.8) |
| Response to frontline therapy, n (%) | |
| Primary refractory‡ | 28 (50.9) |
| Relapsed | 27 (49.1) |
| CR > 1 y | 17 |
| CR ≤ 1 y | 10 |
| Prior cancer-related radiotherapy, n (%) | 15 (27.3) |
| Baseline disease characteristics, n (%) | |
| B symptoms | 12 (21.8) |
| Bulky disease§ | 5 (9.1) |
| Extranodal disease | 17 (30.9) |
| Bone marrow involvement | 9 (16.4) |
ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; AVD, adriamycin, vinblastine, dacarbacine; BEACOPP, bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone; CHOP, cyclophosphamide, adriamycin, vincristine, predinsone; GVD, gemcitabine, vinorelbine, doxorubicin; PD, progressive disease; PR, partial remission; SD, stable disease; VAMP, vinblastine, adriamycin, methotrexate, prednisone.
Number of cycles of frontline therapy was not determined.
One patient received GVD following ABVD, 1 patient received BEACOPP following ABVD, and 1 patient received ABVD following CHOP.
Response to frontline therapy among patients with primary refractory disease included PR (15 patients), PD (10 patients), SD (2 patients), and CR (1 patient).
As assessed per investigator.